ArticleDiscover oncology2025
Identification of novel susceptibility loci for testicular germ cell tumors through multi-omics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to identify potential susceptibility loci for testicular germ cell tumors (TGCT) through a comprehensive multi-omics analysis.
methodsA Mendelian randomization (MR) analysis was conducted to investigate the causal relationships between immune cell phenotypes and TGCT. Summary-based Mendelian Randomization (SMR) and colocalization analyses were subsequently performed to examine candidate phenotypes and TGCT using quantitative trait locis from multiple datasets. Differential gene expression analysis was employed to explore the immune landscape of the target gene in the TGCT tumor microenvironment using UCSC databases. Additionally, potential pathway mechanisms were investigated to elucidate the functional role of candidate genes.
resultsMR analysis identified a significant causal association between the immune cell phenotype HLA-DR on monocytes and TGCT (p = 0.02). SMR analysis revealed that BDH2 was significantly associated with TGCT susceptibility (OR = 0.597, p = 2.21e-07). Colocalization analysis suggested shared genetic variation between BDH2 and TGCT (PP.H4 = 0.95). Immunohistochemistry staining confirmed that BDH2 mRNA levels were significantly lower in TGCT tissues than in normal controls (p < 0.001). In the TGCT tumor microenvironment, lower BDH2 expression was associated with higher immune scores, with T cells and B cells predominantly enriched in the low-expression group, whereas monocytes and endothelial cells were more abundant in the high-expression group. Furthermore, members of the HLA family, exhibited significant correlations between their methylation levels and low BDH2 expression groups. Pathway analysis indicated that BDH2 may influence TGCT progression through the RAS-MAPK signaling pathway.
conclusionsOur findings support a significant susceptibility relationship between the phenotype HLA-DR on monocytes, BDH2, and TGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.